Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 27, 2007

Ipsen Grants Technology to and Takes Stake in PregLem

  • PregLem signed a licensing agreement with Ipsen under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only.

    Sutrepa (an affiliate of Ipsen) has taken a minority equity stake in PregLem and will appoint a representative to its board of directors. PregLem is a biopharmaceutical company specialized in reproductive medicine. It is focused on the development and commercialization of innovative compounds for the treatment of benign gynecological conditions and infertility.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »